Navigation Links
Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
Date:10/12/2009

WELWYN GARDEN CITY, England, October 12 /PRNewswire/ --

- Terms Include up to $200 million in Potential Fees and Milestones Plus Royalties

Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis. The agreement includes upfront and potential milestone payments to Heptares totaling up to $200 million plus royalties. Full financial terms were not disclosed.

StaR technology enables GPCRs, normally membrane-bound, to be worked on in solution, allowing the use of structure-based drug discovery technologies and the discovery of novel drugs addressing this important set of targets. Heptares is deploying this technology principally to generate small molecule drugs against currently difficult or intractable GPCR targets in several disease areas.

Under the terms of the agreement with the Novartis Option Fund, Heptares will apply its StaR technology to a target identified by Novartis and drive a drug discovery programme against that target.

"This is an excellent early deal for Heptares, endorsing our StaR technology and further strengthening our financial position," said Malcolm Weir, CEO of Heptares Therapeutics. "The deal with the Novartis Option Fund demonstrates confidence that our approach can unlock the potential of GCPR targets and forms a solid foundation for other partnerships with leading pharmaceutical companies."

"The potential of GPCRs as targets for drug discovery is well recognized, but it has always been a challenge to gain structural information on GPCRs," said Anja Koenig for the Novartis Option Fund. "We believe that the power of Heptares' technolog
'/>"/>

SOURCE Heptares Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
2. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
3. Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
4. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
5. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
6. Reportlinker Adds Stem Cell Therapeutics Markets Report
7. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
8. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
9. Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference
10. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
11. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... have yet to materialise. Yet, scientists are making ... computers faster. One such approach relies on quantum ... applying an electric field. A new study demonstrates ... quantum dots (TQDs) with electrical impulses can help ... should TQDs be used as quantum information units, ...
(Date:7/24/2014)... 2014 Your cell phone may ... lithium-ion battery storage capacity. , New research indicates ... model created at Lawrence Livermore National Laboratory ... how carbon components will perform as electrodes. , ... urgent need for higher-performance batteries. Several key characteristics ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
(Date:7/24/2014)... , July 24, 2014  Spherix Incorporated (SPEX) -- ... and monetization of intellectual property, today announced that the ... ending June 30, 2014 on Monday, August 18, 2014 ... 10 a.m. ET on Monday, August 18, 2014 to ... by the company,s CEO, Anthony Hayes . ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2
... and biotech,companies are drawing on Singapore,s integrated network ... productivity, leverage academic,insights and diversify risks. Located at ... is representative of key Asian ethnic groups, Singapore ... and develop new solutions for,Asia and beyond. , ...
... an agreement-in-principle to ensure the valorization and the operation under ... Faculty of veterinary medicine in St-Hyacinthe, Quebec, Canada, for human ... ... Laval, Quebec (PRWEB) May 18, 2009 -- Universite de Montreal ...
... Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ... pharmaceuticals in China, today reported,unaudited financial results for the quarter ... -- Total revenue increased to RMB442.5 million ... first quarter of 2009 from RMB394.6 million for the corresponding, ...
Cached Biology Technology:Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 2Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 3Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 4Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 5Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 6Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 7Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 8Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 9Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 10Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 11
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire-iReach/ -- ... managing data from cardiac devices, has cut emergency room ... the UC San Diego (UCSD) Medical Center, according to ... Journal. The UCSD Emergency Departments are using the suite ... such as pacemakers or defibrillators. "Using Geneva,s ...
(Date:7/24/2014)... for food or commercial food sale, has been heavily ... of many species of primates and other mammals. ... of the species being consumed are birds, particularly large ... the meat made available for sale but the meat ... and brought to villages for consumption, we noted a ...
(Date:7/24/2014)... different effects on different species of fish, according ... Bristol and Exeter which tested fish anti-predator behaviour. ... flying seagull predator model when exposed to additional ... minnows. , Lead author Dr Irene Voellmy ... levels in many aquatic environments have increased substantially ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... documents dating back 3,500 years say they have found ... ancient Egypt and not with Hippocrates and the Greeks. ... Biomedical Egyptology at The University of Manchester discovered the ... before Hippocrates was born. , "Classical scholars have ...
... and Gail Williams and Stockholm University's Professor Robin Room examined ... and 2002. , Their results were published in the ... Review. , The men were categorised according to ... is a marker for lower socio-economic status (SES). ...
... Investigator, and Nancy Bae, Ph.D., Postdoctoral Research Associate ... offering insight into the way cells protect chromosome ... tomorrow's issue of Molecular Cell, their paper entitled ... Human Telomeric DNA Ends" employed a biochemical assay ...
Cached Biology News:Egyptians, not Greeks were true fathers of medicine 2Double the death rate from cirrhosis for 'blue collar' men 2Baumann Lab defines proteins that distinguish chromosome ends from DNA double-strand breaks 2
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
Mouse Limitin MAb (Clone 183727)...
Biology Products: